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Open access under CC BY license.Self-assembling peptide-based biomaterials are being
developed for use as 3D tissue engineering scaffolds
and for therapeutic drug-release applications. Chemical
synthesis provides custom-made peptides in small
quantities, but production approaches based upon trans-
genic organisms might be more cost-effective for large-
scale peptide production. Long lead times for developing
appropriate animal clones or plant lines and potential
negative public opinion are obstacles to these routes.
Microbes, particularly safe organisms used in the food
industry, offer a more rapid route to the large-scale
production of recombinant self-assembling biomaterials.
In this review, recent advances and challenges in the
recombinant production of collagen, elastin and de novo
designed self-assembling peptides are discussed.
Introduction
The concept of self-assembly
Self-assembly is ubiquitous in nature at both macroscopic
and microscopic scales and describes the spontaneous
association and organization of numerous individual enti-
ties into coherent and well-defined structures without
external instruction [1]. Molecular self-assembly is charac-
terized by diffusion followed by specific association of
molecules through non-covalent interactions, including
hydrogen and ionic bonds, and hydrophobic and van der
Waals interactions. Individually, such interactions are
weak, but their large numbers will dominate the structural
and conformational behaviour of the assembly [1].
In bionanotechnology, an understanding of how supra-
molecular architectures assemble in nature can lead to the
design and synthesis of novel biomaterials. A range of
complex macromolecules, macromolecular complexes and
structural materials including silks [2,3], collagen [4],
bones [5] and teeth [6] all display self-assembly of building
blocks.
Peptide production
Peptides and proteins have unique biological and self-
assembly characteristics that are increasingly being
exploited for the development of new bioactive molecules
and biomaterials. There are two broad strategies for the
production of peptides: chemical synthesis [7] and recom-
binant production by transgenic organisms ranging
from bacteria and fungi to plants and animals. ChemicalCorresponding author: Kyle, S. (bmbsky@leeds.ac.uk).
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tom-made peptides in relatively small quantities but can
be costly and problematic during process scale-up and as
amino acid sequence length increases; sequences over 35
amino acids are not generally considered to be econo-
mically feasible [8]. In addition, the process employs
chemicals that present potential environmental hazards.
Transgenic animals and plants could provide a cost-effec-
tive alternative and have been used for structural protein
production. However, they are associated with long lead
times, the potential for transfer of harmful animal patho-
gens and/or potential negative public opinion. The use of
microbial ‘biofactories’ for protein synthesis is widely
employed in industry owing to their ease of use, robustness
and lower costs [9]. Such recombinant systems are superior
to chemical synthesis routes for the production of long
peptides (>35 amino acids) and proteins, although there
are significant challenges for the production and efficient
purification of short (10–30 amino acids) self-assembling
peptides.
In this review we focus upon recombinant self-assem-
bling protein and peptide production. Initially, we deal
with natural self-assembling collagen and elastin systems,
which have demonstrated utility for tissue engineering
applications. Finally, we consider progress on de novo
designed short self-assembling peptides.
Collagen and collagen-like proteins and peptides
The collagen superfamily is an abundant group of proteins
that show high complexity, diversity, organization and
function [10]. Collagens are found in all connective tissues
and are a major component of the extracellular matrix.
Because they constitute approximately one-third of mam-
malian body proteins, they are one of the most widely
studied biomaterials. At least 27 different types of collagen
have been identified, and all contain a characteristic triple
helix tertiary structure resulting from the association of
three polypeptide chains containing the sequence repeat
(Gly-X-Y)n, where X is proline and Y is 4-hydroxyproline
[11]. Collagen is synthesized and secreted from cells in the
form of soluble procollagen, which is subject to modifi-
cations catalysed by procollagen metalloproteinases [12],
including removal of N- and C-terminal propeptides,
during the secretion and assembly process. This results
in mature insoluble collagen timers (180 kDa). The C-
terminal propeptide is essential in directing assembly of
the three polypeptide chains into the triple helix structure,Available online 6 June 2009 423
Figure 1. Collagen biosynthesis. (a) This panel shows the major events in collagen fibre assembly. Modifications of collagen include hydroxylation of prolyl and lysyl
residues (1), addition of N-linked oligosaccharides (1) and glycosylation of hydroxylysyl residues in the endoplasmic reticulum (2), before chain alignment and disulphide
bond formation (3), which results in the formation of the procollagen triple helix in the Golgi (4). After export from the cell, the N- and C-terminal propeptides are cleaved (5)
and the resulting tropocollagen undergoes extensive crosslinking and self-assembly into collagen fibrils of diameters between 10 and 300 nm (6). These fibres in turn
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Review Trends in Biotechnology Vol.27 No.7and its removal is a prerequisite for type I collagen fibril
formation [13]. The biosynthesis of collagen and collagen
fibre assembly is shown in Figure 1.
Collagen has been used for medical applications for
centuries. Around 50 AD Pliny the Elder noted that ‘glue
is boiled from the hides of cattle, and the best from those of
bulls’ and hence collagen derives its name from the Greek
words kola, meaning ‘glue’, and gennan, meaning ‘to pro-
duce’ [14]. Over the past 30 years, several collagen-based
medical devices have been approved as a result of extensive
safety profiling and understanding of collagen–cell inter-
actions. Current applications include haemostasis and soft
tissue repair to artificial skin, bone repair and drug deliv-
ery [15]. Collagen from animal sources has long been used
in tissue engineering of heart valves, ligaments and ten-
dons, nerves, cartilage, menisci, and blood vessels, yet the
risks of pathogen transmission and immunogenicity make
such sources clinically undesirable. Another challenge
associated with the use of collagen as a biomaterial is
its degradation, which is facilitated by extracellularmatrix
collagenases. Collagen can be crosslinked to decrease the
rate of degradation; however, there are some concerns over
poor cell infiltration, prevention of remodelling and toxicity
associated with various crosslinking agents. There are
obvious benefits of using recombinant production to gen-
erate safe, mechanically stable, economically viable and
biocompatible collagen-like scaffolds with the potential for
functionalization with bioactive groups [16,17]. Key issues
in producing peptide-based collagen-like materials are
that they (i) mimic the aggregating property of native
collagen and (ii) include biologically active epitopes for
binding integrins for collagen–cell interactions. Although
higher order molecular architectures can be generated
from peptide-based precursors, their physical properties
are distinct from those of native collagen structures [18].
In the expression of recombinant human collagen or
collagen-like polymers, the monomers should assemble to
form the characteristic triple helix, which requires an
expression system capable of performing appropriate
post-translational modifications. To date, over 40 different
genes have been identified that encode specific collagen
chains, and various other genes encode determinants of
collagen maturation and modification. It is thus important
to identify those genes required for different physical and
biological functions, such as triple helix stability, macro-
molecular interactions, aggregating properties, insolubi-
lity and collagen–cell interactions [18]. Several studies
have demonstrated the potential of exploiting key enzymes
for collagen production, including prolyl hydroxylases,
lysyl hydroxylase, disulphide isomerase and lysyl oxidase.
Prolyl 4-hydroxylase-catalysed modifications are crucial
because they produce the 4-hydroxyproline residues that
are integral to the stability of the triple helix. John et al.
[19] were the first to use this enzyme during expression of
recombinant procollagen type I in mouse milk. The mice
contained cDNA constructs encoding procollagen type I
and the a and b subunits of prolyl 4-hydroxylase. Levelsfurther assemble into larger fibres (0.5–3 mm diameter) (7). (b) Histological section of p
ligament fibroblasts, which are stained with haemotoxylin (stains nuclei in blue-purpleof expression of recombinant procollagen in the milk were
in the range of 50–200 mg/L [19].
An alternative to transgenic animals is expression in
mammalian or insect cell lines, which should possess appro-
priate post-translational modification systems. There are
reports of recombinant collagen expression in mammalian
cells [20,21], baculoviral systems [22,23] and plant systems
[24,25]. Stephan et al. [26] expressed recombinant a1(VIII)
and a2(VIII) collagen (60 kDa) in mammalian cells.
When secreted, these monomers formed highly stable tri-
ple-helical trimers (180 kDa) that further assembled
into tetramers (700 kDa) in the presence or absence of
prolyl 4-hydroxylase [26]. Limitations of such systems are
that levels of collagen production are generally low and not
easily detectable by western blot analysis and that cells
grow relatively slowly and require complex media.
Compared with mammalian and insect cell systems,
yeasts have the advantage that they can produce much
larger quantities of recombinant proteins and have some of
the advantages of prokaryotic hosts, such as rapid doubling
times, high cell densities and growth on simple media. The
methylotrophic yeast Pichia pastoris was engineered to
express prolyl 4-hydroxylase, allowing the successful pro-
duction of accurately hydroxylated triple-helical type I and
III recombinant human collagen to high levels [27].
In a plant-based approach, Merle et al. [25] demon-
strated via transient expression that hydroxylation of pro-
line in collagen is possible by co-expression with prolyl 4-
hydroxlyase a and b subunits. They then generated stably
transformed tobacco plants expressing the three genes and
demonstrated the production of recombinant hydroxylated
homotrimeric collagen [25].
Du et al. [28] have produced a recombinant collagen-like
protein in the bacteriumEscherichia coli, which has advan-
tages of rapid cell growth, high-level protein expression,
simple media and low cost. The collagen-like proteins were
expressed with a C-terminal foldon sequence derived from
the phage T4 fibritin to stabilize the triple helix, and yields
of purified proteins were around 90 mg/L culture. Cell
responses to the recombinant protein were found to be
better than those to native collagen, suggesting its poten-
tial for biomaterial applications [28].
Elastin and elastin-like proteins
Elastin is an extracellular matrix protein found in connec-
tive tissue, where it provides elasticity and resilience to
tissues requiring extensibility and recoil, including large
blood vessels such as the aorta, lung parenchyma, liga-
ments, skin and elastic cartilage [29]. It is a highly inso-
luble, crosslinked polymer synthesized in vivo as soluble
tropoelastin monomers (66 kDa), which become exten-
sively crosslinked in the extracellular matrix, forming
large complex arrays. Elastin is composed of hydrophobic
domains that are rich in glycine, valine and proline resi-
dues and of crosslinking domains that are rich in lysine
and alanine. The alanine residues provide spacers, allow-
ing the display of the lysine residues [30]. The extensiveorcine patellar tendon showing a large number of intertwined collagen fibres with
) and eosin (stains collagen fibres in pink). The scale bar represents 25 mm.
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important in stabilizing the polymer, which after its stabil-
ization shows little degeneration with age [31,32].
Elastin from native sources has received less attention
than collagen for biomaterial applications owing to the
complexity of its purification [33] and its association with
the glycoprotein fibrillin, which confers a high propensity
to calcify upon implantation [34]. Hence recombinant sys-
tems for producing elastin have been established [35], and
this material has been used in the form of gels or fibres as
injectable scaffolds for cartilage tissue repair [36,37] and
soft tissue replacement [38].Figure 2. Elastin fibres. (a) This panel schematically illustrates the formation of elastic f
transported to the cell surface membrane, where crosslinking by lysyl oxidase aids in t
with microfibrillar proteins, such as fibulin-4 and/or fibulin-5, thereby facilitating cro
transferred to extracellular microfibrils, which interact with the cell through integrins (2
transfer of aggregates to the microfibril. Elastin aggregates assembled on the microfi
fibulin-5. Additional crosslinking by lysyl oxidase then leads to completion of the elasti
aortic valve leaflet stained with Miller’s elastin stain. The elastic fibre entanglements a
426The mechanism of tropoelastin monomer assembly into
a polymeric matrix is not well understood, although the
formation of intermediate aggregates is likely to have an
organizational role in the alignment of tropoelastin mono-
mers before crosslink formation and polymer assembly
[39]. The hydrophobic domains of elastin have been shown
to contribute to assembly based primarily upon the specific
nature of the amino acid sequences of these domains [30].
It is evident that the self-assembly processes involved in
elastin formation are complex and require further inves-
tigation. One proposed model for elastic fibre assembly is
illustrated in Figure 2 [40].ibres and their assembly. After translation and prolyl hydroxylation, tropoelastin is
ropoelastin aggregation (1). Cell surface proteins might assist the initial assembly
sslinking. The resulting aggregates remain on the cell surface before they are
). Several microfibrillar proteins interact with tropoelastin, which might help in the
bril coalesce into larger structures under possible participation of fibulin-4 and/or
c fibre (3). Adapted from [40] with permission. (b) Histological section of a porcine
re shown in dark blue/black. The scale bar represents 50 mm.
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ture, pH and ionic strength, can result in tropoelastin self-
aggregation by the process of coacervation [31,41]. This is
a reversible process by which, for example, an increase in
temperature leads to soluble protein partitioning from the
solvent to an aggregated phase [42]. The lower the coa-
cervation temperature of a molecule, then the higher will
be its propensity for self-aggregation [43]. Repeats of the
pentapeptide sequence VPGXG, where X is an amino acid
other than proline, have been produced recombinantly as
oligomeric repeats giving rise to elastin-like proteins
(ELPs) with properties that make them good candidates
for tissue engineering and cancer therapy applications
[44]. ELPs, like natural elastin, become more ordered
owing to coacervation [45].
The Urry group [39,45] has made a major contribution
in the area of production of recombinant ELPs based on a
VPGVG sequence with additional cell attachment
sequences (GRGDSP). These ELPs proved to be biocompa-
tible and non-cytotoxic to bovine aortic endothelial cells
and to Ligamentum nuchae fibroblasts [39,45]. Urry and
colleagues also showed that elastin-like materials contain-
ing the sequence G-(VPGVG)19-VPGV fused to glutathione
S-transferase could be produced in E. coli. After cleavage
with protease Factor Xa, the final ELP yield was 1.15 mg/L
fermentation culture [46]. Betre et al. [36] used the
temperature-induced coacervation property of ELPs at
35 8C for injectable scaffold development for cartilage
repair. Below 35 8C the ELPs are soluble, thereby allowing
the incorporation of cells with the ELP solution below body
temperature. Upon injection at the defective site the
temperature would increase and the ELPs would form a
gel-like matrix encapsulating the cells. It was shown that
chondrocytes maintained their rounded morphology and
phenotype and produced extracellular matrix components
in vitro. This ELP coarcervate showed comparable mech-
anical properties to those reported for collagen and glyco-
saminoglycans [36] and thus showed promise for cartilage
tissue engineering. In another study, McHale et al. [47]
designed an ELP capable of undergoing enzyme-initiated
gelation catalysed by transglutaminase.
Woodhouse et al. [48] investigated the use of a recombi-
nant human ELP as a coating on synthetic materials to
determine whether it could improve blood compatibility of
cardiovascular devices, such as vascular conduits and
arterial/venous catheters. The ELP constructs were based
on EP20-24-24 (17 kDa), which comprised exons 20, 21,
23 and 24 of human elastin and contained hydrophobic and
crosslinking domains, and were produced as fusions to
glutathione S-transferase (GST) [30] in E. coli.
Girotti et al. [49] expressed ELPs based on the sequence
motif (VPGIG)2VPGKG, in which the lysine (K) replaced
isoleucine (I) in every third repeat to allow crosslinking to
occur. The ELP monomer also contained a fibronectin CS5
domain, which includes the REDV endothelial cell recog-
nition sequence. They expressed a range of repeat sizes and
purified a decamer (80 kDa) using an E. coli expression
system. The purified protein was crosslinked by glutaral-
dehyde and resulted in insoluble hydrogel matrices [49].
Taken together, these reports demonstrate that via
coacervation and further stabilization, ELPs have greatpotential as tissue engineering substrates. It is particu-
larly exciting that recombinantly produced ELPs respond
to physicochemical triggers and undergo transition to
hydrogels. Recombinant production therefore offers a sus-
tainable method for producing large quantities of ELPs
incorporating bioactive domains and cell recognition sites.
De novo designed self-assembling peptides
During the last decade, many studies have focused on the
design and use of artificial self-assembling peptides for
tissue engineering [50–54] and most of these have
exploited chemically synthesized peptides. Zhang and cow-
orkers [1] have made a major contribution through their
systematic investigation of peptide systems, providing
insights into the chemical and structural principles that
dictate the self-assembly process. The peptide systems
developed include ‘molecular Lego’, which can form hydro-
gel scaffolds for tissue engineering, ‘molecular switches’,
which can act asmolecular actuators, ‘molecular hooks and
Velcro’ for surface engineering, ‘molecular capsules’ for
protein and gene delivery and ‘molecular cavities’ for bio-
mineralization [1]. Schematic illustrations of self-assem-
bling peptide systems are shown in Figure 3.
One of the first commercially available self-assembling
peptides designed by Zhang was RAD16 (RADARADAR-
ADARADA), which was marketed under the name of Pur-
aMatrixTM (3DM, Inc., Cambridge, MA, USA). This 16
amino acid peptide self-assembles into a nanofibre net-
work. It is easy to synthesize chemically and can be for-
mulated in water at concentrations up to 50 mg/mL. Gel
formation can be triggered by an increase in ionic strength
or by a change in pH. This peptide has been used in a wide
range of biomaterial applications, including cartilage tis-
sue repair [55], osteoblast proliferation and differentiation
[56], bone regeneration in bone defects [57] and axon
regeneration [58].
Control over the process of self-assembly is crucial to the
design of peptide systems that assemble and disassemble
with physicochemical cues, including pH, light, ionic
strength, temperature and concentration. pH switching,
for example, is a relatively simple approach for controlling
self-assembly. An example is the self-assembling b-peptide
P11-4 (QQRFEWEFEQQ), which is pH sensitive due to the
ionizable glutamate and arginine side chains. At concen-
trations below <10 mg/mL it is soluble at neutral pH but
adopts a hydrogel state at low pH (pI 4.2) by self-assem-
bly of anti-parallel b-sheet tapes, which then stack
together to form fibrils. It will also form a hydrogel state
above a critical concentration (>10 mg/mL) at pH 7.4 and a
salt concentration of 140 mM in cell culture medium [59],
with applications including enamel remineralization [60],
injectable scaffolds [61] and joint lubricants [62]. A series of
related self-assembling peptides have also been designed
[63,64].
The Schneider group [65] have similarly designed
MAX1 and MAX8 b-hairpin peptide systems, in which
folding and hydrogel formation is initiated by the high
salt content of cell culture medium at pH 7.4. In water,
MAX1 is an unfolded monomer, but addition of sodium
chloride to 150 mM and a pH change to 7.4 results in
formation of a rigid hydrogel [65]. The P11 and MAX427
Figure 3. Schematic illustration of various self-assembling peptide systems [1]. Molecular ‘Lego’ forms b-sheet structures through interactions between hydrophobic and
hydrophilic domains. These peptide systems are able to undergo complementary ionic bonding with the hydrophilic surface. Molecular ‘switches’ change their molecular
structure upon changes in temperature. Molecular ‘Velcro’ forms monolayers on surfaces through covalent bonds between a cysteine anchor and gold atoms on the
surface. Surfactant-like peptides can undergo self-assembly to form either nanovesicles or nanotubes, as shown.
Review Trends in Biotechnology Vol.27 No.7systems use an alternating hydrophobic and hydrophilic
amino acid pattern to dictate a b-sheet structure via
interchain hydrogen bonding.
The Woolfson group have designed peptides based on
helical coiled-coils [66–68], allowing them to elucidate the
design principles that underpin self-assembly of such
peptide systems. They reported studies based on a heptad
sequence repeat, abcdefg, with isoleucine and leucine at
the a and d sites, respectively, ensuring coiled-coil dimer-
ization. To direct staggered assembly of peptides and fibril
formation, they incorporated lysines at the ends of the
peptides with central glutamates to allow ionic inter-
actions. The resulting fibres were straight rods, tens of
microns in length, providing a good model for the devel-
opment of functional biomaterials [69]. The Hartgerink
group [70] have also usedheptad repeats producing helical
coiled-coils that form nanofibres in a concentration-de-
pendent manner. This group also used pH and ionic
strength as triggers for self-assembly with incorporation
of isoleucine and leucine residues at positions a and d of
the heptad, and glutamates at positions e and g providing
an acidic region. Hence at low pH ionic repulsion is elimi-
nated and carboxylic acid side chains hydrogen bond with
each other [70].
The Raines and Koide groups [71,72] have developed
peptide systems for creating elongating triple-helical supra-
molecules via intermolecular interaction between trimeric
collagen-like peptides. The initial trimeric peptide assem-
blies were facilitated by using two [71] or three [72] peptide
repeat sequences with Cys residues that were differentially
positioned to allow association of a staggered arrangement
of peptides into a trimer, thus providing overhanging
tails for association with other trimeric units and resul-
ting in collagen triple helices up to 400 nm in length
that resemble natural collagen fibrils. These examples of428peptides of 30 amino acids demonstrate a minimalist
approach to developing collagen-based biomaterials with
tuneable attributes by exploiting triple-helical propensity
to direct self-assembly.
Recombinant peptide production
Most of the self-assembling peptides in use have been
produced through chemical synthesis, which also allows
a wide range of amino acid analogues to be incorporated.
Recombinant self-assembling peptide production is also
being explored. The main advantages are the provision
of sustainable sources of biomaterials and the ability to
readily produce modified variants containing quite large
bioactive motifs or domains. Biological peptide production
is, however, generally restricted to using the 20 naturally
occurring amino acids, although bioincorporation of unna-
tural amino acids into proteins and peptide is now becom-
ing more feasible [73].
In the early 1990 s, Kuliopulos and Walsh [74] used a
tandem repeat approach (Box 1) for the production of a
soluble 14 aa peptide. They added peptide repeats to
ketosteroid isomerase (KSI), a 125 amino acid protein
that becomes localized in insoluble inclusion bodies in E.
coli, together with a C-terminal 6His-tag for purification.
The KSI-(peptide)5-His6 was expressed, purified by Ni
affinity chromatography and cleaved with cyanogen bro-
mide (CNBr) at intervening methionine residues. The
peptide units all terminated with homoserine lactone
derived from the C-terminal methionine. They reported
a respectable yield of 50–55 mg/L of pure peptide after
high performance liquid chromatography (HPLC).
Although this peptide was not self-assembling, the work
demonstrated the potential to produce short peptides by
recombinant means. The C-terminal homoserine lactone
that is formed after CNBr cleavage of the tandem repeats
Box 1. Tandem repeat strategy for peptide production
The tandem repeat strategy was introduced by Shen [85] and involved
peptide sequences that are separated by cleavable amino acids,
usually Met or Cys. This approach was tested for proinsulin
expression, which at 90 amino acids represents a small protein rather
than a peptide. Unimer, dimer and trimer constructs were tested, with
the trimer giving the highest yield of proinsulin. More relevant to the
production of short self-assembling peptides is the strategy in which
tandem repeats, again separated by a cleavable residue, are
expressed as part of a fusion protein to assist in expression, stability
and recovery. Because the fusion partner protein will be substantially
larger than the peptide, the peptide will represent only a small
proportion of the recombinant protein, and increasing the number of
tandem repeats should increase the yield of peptide. For a small
carrier protein of 130 amino acids fused to a single 12 amino acid
peptide, the relative levels of carrier protein and peptide would be
91.5% and 8.5%, respectively. However, if tandem peptide repeats
are included, the respective proportions of carrier and peptide are
expected to alter, as shown in Table I. Unfortunately, this theoretical
relationship between increasing number of repeats and their final
yield is not commonly observed. Kuliopulous and Walsh [74]
systematically expressed tandem repeats of a soluble 14 amino acid
yeast mating factor peptide fused to a ketosteroid isomerase carrier
protein. Expression levels increased up to three repeats before
becoming lower up to six repeats, with a further dramatic reduction
at higher numbers of repeats. For a histonin peptide, Kim et al. [86]
tested a series of two to 32 repeats and found the highest levels of
expression for a 12-mer. For self-assembling peptides, this decrease
in expression of the recombinant protein with increasing number of
repeats has also been observed [78,79]. For most examples of peptide
production, the recombinant fusion proteins are expressed as
inclusion bodies that should, in theory, protect the cell from any
potential adverse effects of the peptide, as well as protecting the
peptides from degradation, but perhaps the longer repeat sequences
are not prevented from causing cell damage. Until the underlying
reasons for the failure of expression of longer tandem peptide repeats
is understood, the use of a small fusion partner and a single peptide
repeat seems to be the most feasible expression strategy.
Table I. Effect of increasing peptide repeat number on
theoretical yields of carrier protein and peptide
Peptide repeat
number
Yield of carrier protein
(%)
Yield of peptide
(%)
2 84.4 15.6
3 78.3 21.7
4 73.0 27.0
5 68.4 31.6
6 64.4 35.6
9 54.6 45.4
Review Trends in Biotechnology Vol.27 No.7could, however, have adverse effects on self-assembling
peptides and their bioactivity. Conversely, it could also
prove beneficial in some cases by providing a mechanism
for physically coupling the peptide to a solid support.
Many groups prefer not to use CNBr due to its toxicity,
and instead use site-specific proteases as a cleavage system
mechanism. Affinity purification with a suitable fusion tag
allows recovery of the target protein/peptide, which can be
released from the fusion partner by incubation with the
site-specific protease. Various approaches for specific clea-
vage of recombinant proteins are illustrated in Table 1, and
systems for protein or peptide production are shown in
Table 2.Table 1. Commonmethods to cleave peptides at specific amino
acid sequences
Cleavage agent Cleavage
specificity
Chemical
Hydroxylamine -N # G-
Cyanogen bromide -M # X-
Formic acid -D # P-
2-iodosobenzoic acid -W # X-
3-bromo-3-methyl-2-(2-nitrophenylthio)-3H-indole -W # X-
2-nitro-5-thiocyanatobenzoic acid -C # X-
1-cyano-4-dimethylaminopyridiumtetrafluorobo-
rate
-C # X-
Enzymatic
Enterokinase -DDDDK # X-
SUMO protease SUMO-GG # XXX-
TEV protease -ENLYFQ # (S,G)-
Factor Xa -IDGR # X-
Thrombin -LVPR # GS-
HRV 3C protease -LEVLFQ # GP-
IGase -PP # YP-
Furin -RX(R/K)R # X-
Endoproteinase Lys-C -K # X-
Endoproteinase Glu-C -E # X-
Endoproteinase Arg-C -R # X-
Endoproteinase Asp-C -D # X-Recombinant self-assembling peptide production
Recombinant technology has been increasingly used for
self-assembling peptides. Reed et al. [75] used a cellulose-
binding domain as a fusion partner for tandem repeats of
RAD16. Glutamic acid residues were introduced before and
after each repeat to allow endoproteinase GluC mediated
cleavage of the peptide units. The fusion protein was
affinity-purified on cellulose, a low cost matrix [75]. The
main problem was the low level of recovery of purified
peptide, which was only 5% of the expected yield. The
reasons for such losses are not completely clear, but con-
tributing factors were probably the protease cleavage step
and the concentration-dependent self-assembly, which
might have resulted in insoluble aggregated material.
Many natural proteins can misfold to form protein and
peptide aggregates that can contribute to the pathology of
diseases such as Parkinson’s, Alzheimer’s and type II
diabetes. To understand and subsequently develop thera-
peutic interventions, both structural and biochemical stu-
dies of relevant peptides are necessary, demanding large
quantities of the biologically relevant peptide. For
example, the expression and purification of a recombinant
peptide comprising residues 11–26 of the Alzheimer’s b-
amyloid protein (Ab11–26) has been reported [76]. Three
tandem repeats of Ab11–26 were fused at the C-terminus of
KSI, and the fusion protein was purified using Ni-affinity
chromatography and HPLC, resulting in 10 mg peptide/L
culture. This Ab11–26 peptide formed fibrils that exhibited a
similar morphology to those formed by the chemically
synthesized peptide [76].
vanHell et al. [77] reported on the production of two self-
assembling peptides designed to form vesicles in aqueous
solution – SA2 (AAVVLLLWEE) and SA7 (AAVVLLL-
WEEEEEEE). These were produced as fusions to the
SUMO protein, and the peptides were released by diges-
tion with the site-specific SUMO protease. A 5-litre fer-
mentation was reported to yield 300 mg of fusion protein429
Table 2. Overview of recombinant protein/peptide production systems
Protein/peptide Proteins/peptides expressed Structures formed Expression
system
Yield mg/L Refs
Homotrimeric human type
I collagen
Homotrimeric collagen type I, chimeric prolyl
4-hydroxylase
Not reported Transient
expression in
tobacco plants
Not
reported
[24]
Procollagen Procollagen a2 chain, and a/b subunits of
prolyl 4-hydroxylase
Not reported Transgenic
mice – mouse
milk
50–200 [22]
Collagen type VIII a1(VIII) and b1(VIII) chains. Co-transfection
with prolyl 4-hydroxylase
Rod-like molecules
and hexagonal
lattices
293-EBNA
mammalian cells
Not
reported
[26]
Human collagen type I and III Substitution of a C-propeptides of proa1(I),
proa2(I) and proa1(III) chains with a foldon
region, co-expression with prolyl 4-hydroxylase
Not reported Pichia pastoris Not
reported
[27]
Collagen-like protein Incorporation of a T4 foldon region
(GYIPEAPRDGQAYVRKDGEWVLLSTFL)
Fibrils Escherichia coli 90 [38]
Elastin-like polypeptides Derivatives of PGVGVA Various states of
coarcervation, from
globular structures
to fibrils
Escherichia coli Not
reported
[30,48]
Elastin-like polypeptides (VGVPGVGVPGGGVPGAGVPGVGVPGVG
VPGVGVPGGGVPGAGVPGGGVPG)9
Gel-like coarcervates Escherichia coli Not
reported
[36]
Elastin-like polypeptides with
incorporated cell recognition
motifs
(VPGIG)2VPGKG(VPGIG)2EEIQIGHIPREDV
DYHLYP(VPGIG)2VPGKG(VPGIG)2(VGVAPG)3
Not reported Escherichia coli Not
reported
[49]
P11-2 QQRFQWQFEQQ b-sheet forming fibrils Escherichia coli 2.63 [78]
P11-4 QQRFEWEFEQQ b-sheet forming fibrils Escherichia coli 90 [79]
RAD16 peptide RADARADARADARADAE Nanofibres Ralstonia eutropha 10.1 [75]
Ab11–26 peptide EVHHQKLVFFAEDVG Amyloid fibrils Escherichia coli 10 [76]
SA2 AAVVLLLWEE Vesicle-forming
peptides
Escherichia coli 6 [77]
SA7 AAVVLLLWEEEEEEE
Review Trends in Biotechnology Vol.27 No.7and 30 mg of purified peptide/L culture after HPLC, which
suggests 100% efficiency of peptide recovery [77].
Middelberg and colleagues [78] produced the self-
assembling peptide, P11-2 (QQRFQWQFEQQ), which formsFigure 4. Example of the tandem-repeat strategy for high yield peptide production in
(KSI) is targeted to inclusion bodies in E. coli together with tandem repeat peptides enco
with cyanogen bromide (CNBr), which acts on intervening methionine residues. This r
peptide monomer.
430a concentration-dependent hydrogel. They expressed P11-2
as unimer, dimer, trimer or nonamer constructs fused to
KSI, but rather than using CNBr cleavage of methionine,
they chose cleavage of cysteine residues by 1-cyano-4-the pET31b expression vector. A fusion protein comprising ketosteroid isomerase
ding the P11-4 sequence and a His tag. The fusion protein and peptides are cleaved
esults in the presence of a C-terminal homoserine lactone (hsl) on each resulting
Review Trends in Biotechnology Vol.27 No.7dimethylaminopyridinium tetraflouroborate. Levels of
protein expression were relatively low, although recovery
of 2.63 mg peptide/L culture after reverse phase (rp)HPLC
nevertheless represented an efficient 42% purification of
peptide [78].
We have used KSI fusion and CNBr cleavage for
recombinant production of a similar self-assembling
peptide P11-4 as a trimer repeat [79] (Figure 4). Host
strain optimization and the use of autoinduction
[80] allowed enhanced levels of fusion protein and
hence peptide production, resulting in the recovery of
2.5 g of fusion protein/L culture. There was loss of
peptide at the purification stage because a theoretical
yield of ca. 500 mg peptide/L culture only translated
into the recovery of ca. 90 mg/L. Nonetheless, we believe
this is the highest level of self-assembling peptide recov-
ery so far reported from a recombinant system.
This work also emphasizes that optimizing growth con-
ditions can maximize peptide production levels. Cru-
cially, more research is required into optimizing the
approaches for efficient recovery of the expressed self-
assembling peptides.
Conclusions
The examples outlined here show that self-assembling
biomaterials can act as scaffolds for tissue engineering
and show tremendous promise in regenerative medicine.
‘Smart’ self-assembling peptides are able to respond to
physicochemical triggers, such as concentration, pH and
temperature, and are therefore ideal candidates to act as
new scaffolds for tissue engineering applications. Bioma-
terials with the addition of cell recognition motifs, such as
RGD, have already been examined in chemically synthes-
ized peptides [81–84]. The production of short (10–30
residues) self-assembling peptides by recombinant tech-
nology is in its infancy, but these can be readily engin-
eered to contain cell recognition sites and larger bioactive
domains to provide significant benefits for tissue engin-
eering applications. There is clear potential for the com-
bined use of both chemically and biologically synthesized
self-assembling peptides. For example, one could imagine
chemically synthesized peptides providing the bulk com-
ponent of a matrix supplemented by the addition of more
complex self-assembling peptide-associated bioactive
domains, produced by recombinant approaches, and
which would integrate stochastically during the self-
assembly process to provide an ideal environment for cell
growth. Bioproduction of short self-assembling peptides
has also been shown to be feasible using microbial sys-
tems. Even with E. coli, substantial amounts of peptide
can be produced, although care must be taken to ensure
that factors such as endotoxins are absent. Yeasts have
been less well explored in this area, yet many yeast
strains are capable of very high levels of protein pro-
duction, and some have ‘Generally Regarded As Safe’
(GRAS) status due to their prolonged use in the food
industry. In the future, however, if recombinant pro-
duction can be translated into transgenic animals and
particularly transgenic plants, the quantities of peptides
that could be produced relatively cheaply in a sustainable
manner would be essentially unlimited.Acknowledgements
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